Calliditas Q4 2023: Enters 2024 with a strong momentum - Redeye
Börskollen - Aktier, fonder och ekonominyheter

Börskollen

För dig med koll på börsen

Aktieanalys

Calliditas Q4 2023: Enters 2024 with a strong momentum - Redeye

{newsItem.title}

Calliditas confirms that 2024 has continued with a positive launch momentum. This is probably the most essential aspect of the Q4 result following the trading update from 8 January. The early conservative guide is the main surprise, which also introduces a higher level of uncertainty regarding the initial market reaction. Our Calliditas Base Case is SEK 280 (Bull SEK 415 and Bear SEK 70).

Länk till analysen i sin helhet: https://www.redeye.se/research/983409/calliditas-q4-2023-enters-2024-with-a-strong-momentum?utm_source=finwire&utm_medium=RSS

Nyheter om Calliditas Therapeutics

Läses av andra just nu

Om aktien Calliditas Therapeutics

Senaste nytt